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ABSTRACT 
 
Accumulating evidence suggests flavonoid intake is associated with reduced risk of non-
communicable diseases. We aimed to systematically determine and quantify the potential 
association between dietary anthocyanin intake and risk of cardiovascular diseases (CVD). A 
systematic literature search of studies reporting anthocyanin intake and risk of fatal or nonfatal 
CVD was performed using SCOPUS, MEDLINE, CINAHL and Cochrane Library. The 
relative risk (RR) or hazard ratio (HR) of highest category of anthocyanin foods were pooled 
in a random-effects meta-analysis. Subgroup analysis were conducted to determine possible 
sources of heterogeneity. The meta-analysis suggested intake of dietary anthocyanins and 
reduced risk of CHD (RR = 0.91, 95% CI: 0.83, 0.99; I2 = 12.0, Ph = 0.337) and CVD mortality 
(RR = 0.92, 95% CI: 0.87, 0.97; I2 = 0.0, Ph = 0.584). However, there was no relationship 
between the intake of these compounds and reduced risk of MI, stroke or total CVD. Subgroup 
analysis determined reduced risk of CHD and CVD mortality was more prominent for 
anthocyanidin intake, as opposed to anthocyanin or berries. Our systematic review and meta-
analysis provides evidence that anthocyanins, specifically anthocyanidins, reduce the risk of 
CHD and CVD mortality. Further randomised controlled trials on anthocyanin intake and CVD 
risk factors are needed to support these findings. 
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INTRODUCTION 
 
Historically, berry and cherry plant products have been widely utilized as medicinal sources to 
treat and prevent a number of ailments, including, but not limited to; stomach-aches, 
snakebites, inflammation, fevers and pains (Hummer, 2010; Stewart, 2003). More recently, 
there is robust epidemiological evidence that a diet rich in berry fruits is associated with a 
reduced risk of non-communicable and neurodegenerative diseases (Devore et al., 2012; Guo 
et al., 2016; Huang et al., 2016). Such health benefits are thought to be attributable to their 
naturally occurring flavonoids, which are further sub-classified into flavonols, flavones, 
flavanones, flavan-3-ols, isoflavones, and anthocyanins (Wang et al., 2014). Liu and colleagues 
(2017), recently demonstrated through a dose-response meta-analysis that increased intake of 
dietary flavonoids was associated with reduced risk of all-cause mortality. Similarly, Wang et 
al. (2014), reported flavonoid intake was associated with reduced risk of cardiovascular disease 
(CVD). However, individual flavonoids might not be equally associated with cardioprotection, 
given the extensive differences that exist between their bioavailability and bioactivity. Notably, 
berry fruits are rich in the subclass of flavonoids anthocyanins, which evidence suggests the 
bioavailability to be greater than previously estimated (Czank et al., 2013). Anthocyanins (from 
the Greek anthos, a flower, and kyanos, dark blue) are important secondary plant metabolites 
that occur primarily as glycosides of their aglycone anthocyanidins (Figure 1). They are water-
soluble pigments often responsible for the orange, red, and blue colours in fruits, vegetables, 
flowers, and other tissues in plants (Delgado-Vargas et al., 2000). Hence are most abundant in 
commonly consumed fruits that are dark red and purple, such as blackberries, raspberries, 
strawberries, blueberries, red grapes and cherries (Clifford, 2000; Horbowicz et al., 2008). 
Accumulating evidence substantiates that anthocyanins have a putative role in overall 
cardiovascular health (Reis et al., 2016). 
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Recent in vitro studies have established that anthocyanin metabolites are just as bioactive, if 
not more, than their parent compounds (Amin et al., 2015; Keane et al., 2016). They have been 
demonstrated to elicit vasoprotective properties such as antioxidant, anti-inflammatory, anti-
atherogenic and vasodilatory actions (Castaneda-Ovando et al., 2009; Edwards et al., 2015; 
Wang et al., 1999) and there is now a growing body of evidence also supports that intake of 
dietary anthocyanins can improve functional vascular health in vivo (Fairlie-Jones et al., 2017; 
Jennings et al., 2012). The potential underlying mechanisms for the aforementioned might 
involve the augmentation of endothelial-derived nitric oxide (NO) bioavailability. 
Anthocyanins can directly increase NO through upregulation of the endothelial nitric oxide 
synthase and L-arginine pathways, but also indirectly by potentiating the nitrate-nitrite-NO 
pathway, and minimising degradation of NO via their antioxidant actions (Edwards et al., 2015; 
Rocha et al., 2014). Nitric oxide is an integral molecule in regulating endothelial homeostasis 
and anthocyanin-rich foods have previously been demonstrated to improve endothelial function 
(Rodriguez-Mateos et al., 2013), which has been replicated in studies that supplemented with 
purified anthocyanins (Zhu et al., 2011).  Accordingly, in a recent attempt to evaluate the effect 
of flavonoid intake on mortality, subgroup analysis determined significant decreases in risk of 
CVD mortality associated with the highest intake of anthocyanidins (Summary relative risk = 
0.89, 95% CI: 0.83, 0.95) amongst 5 cohorts (Grosso et al., 2017). However, as highlighted by 
these and other authors (Grosso et al., 2017; Hooper et al., 2008), there is a need for a better 
understanding of the role of specific flavonoid subclasses in relation to health and disease. 
Moreover, there is inherent structural complexity among different flavonoids and diversity 
between flavonoid-containing foods and only CVD mortality was investigated (Grosso et al., 
2017). Thus, conceptually it is possible that encompassing all flavonoids resulted in missing 
studies that evaluated anthocyanin-rich foods and the relationship between the intake of these 
compounds and risk of CVD incidence has not recently been determined since Wang and 
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colleagues (2014) previously reported significant reductions in CVD risk associated with 
intake of anthocyanidins (RR = 0.89, 95% CI: 0.83, 0.96; I2 = 0.0, Ph =0.741) in a subgroup 
analysis of 3 studies. Therefore, the aim of the current meta-analysis was to evaluate the 
quantitative relationship between dietary intake of parent anthocyanidin compounds and/or 
anthocyanin-rich foods and the risk of CVD and related mortality from prospective cohort 
studies. 
 
METHODS 
Search strategy 
This review followed the preferred reporting items for systematic reviews and meta-analysis 
(PRISMA) guidelines (Stroup et al., 2000). The protocol of this systematic review was pre-
registered with PROSPERO, the International Prospective Register of Systematic Reviews 
[registration number: CRD42018089121].  A systematic literature search was performed using 
SCOPUS, MEDLINE (ProQuest), CINAHL (EBSCO) and Cochrane Library from inception 
until January 2018. The search strategy was conducted using Medical Subject Heading 
(MeSH), Boolean operations and formed from existing reviews of anthocyanin-rich foods 
(Fairlie-Jones et al., 2017), collated in three key concepts; (i) anthocyanins, (Hashimoto et al.) 
cardiovascular disease and (iii) prospective study design. Furthermore, the reference list of 
retrieved systematic reviews and included studies were hand searched to find potential articles 
that could be included in the current meta-analysis.  
 
Study selection 
Studies were included for analysis if they met the following inclusion criteria: 1) were a 
prospective study in adults (≥ 18 years) including; prospective cohort, nested case-control and 
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case-cohort studies; 2) included ≥ 2 doses of anthocyanins or anthocyanin-rich foods as 
exposure; 3) reported fatal or non-fatal CVD events as outcome of interest [i.e. coronary heart 
disease, ischemic heart disease, coronary artery disease, angina, myocardial infarction, heart 
failure, cerebrovascular disease (ischemic stroke and haemorrhagic stroke), peripheral artery 
disease, CVD mortality]; 4) reported relative risk (RR) or hazard ratio (HR) and their 
corresponding 95% confidence intervals (or sufficient data to compute them). Titles and 
abstracts were independently reviewed using Covidence systematic review software (Veritas 
Health Innovation, Melbourne, Australia) by two researchers (RK and GH). Only full texts that 
were published in English or had an existing translation were retrieved and examined.  
 
Data extraction and quality assessment 
Data was independently extracted into piloted forms by two investigators (RK and KMK) in 
accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines (Stroup et al., 2000). Any discrepancies were resolved by reviewing the original 
article. The following data was extracted from each study: the first author’s last name(s), 
publication date, location, the cohort name, participant’s age (at baseline) and sex, the follow 
up period, the method of dietary assessment and anthocyanin exposure range, type of outcome, 
number of cases, HR or RR and their corresponding 95% CI and any covariate adjustments. 
Quality of each study was evaluated using the nine-star Newcastle-Ottawa scale (Stang, 2010), 
which assesses three major domains; selection of the study group (0–4 stars), comparability 
(0–2 stars) and outcome in the cohorts (0–3 stars). A maximum of 9-stars could be awarded, 
where 0-3, 4-6 and 7-9 stars were regarded as low, moderate and high quality, respectively. 
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Statistical Analysis 
A random-effects meta-analysis was conducted because of unexplained heterogeneity between 
studies, where the common measure was RR. All included studies used COX’s models, 
therefore HR were directly considered as RRs. The multivariate-adjusted RR and standard 
errors (SEs; derived from their corresponding 95% CIs) were logarithm transformed. If 
individual studies reported RR for multiple outcomes of CVD, or were stratified by gender, the 
risk estimates were pooled by fixed-effects model and the summary estimate was used in the 
main meta-analysis (Aune et al., 2017).  
Sensitivity analysis was performed by omitting one study at a time to evaluate the potential 
bias and robustness of the overall risk estimate. Heterogeneity between studies was determined 
by χ2 by Cochran’s Q test (significance level at Ph < 0.10) (DerSimonian and Laird, 1986) and 
the I2 statistic. For the I2 statistic, I2 values ≤25%, ≤50%, ≤75% and >75% indicated no, little, 
moderate and significant heterogeneity, respectively. Subgroup analysis was conducted to 
determine possible sources of heterogeneity. Subsequently, the effect of exposure, type of 
outcome, sex, location, sample size and follow-up length of the included studies evaluated. 
Potential publication bias was evaluated by Egger’s test (P < 0.10) and visual inspection of 
funnel plots (Begg and Mazumdar, 1994). All statistical analysis was conducted using STATA 
v.15.0 (StataCorp, College Station, Texas, USA), P < 0.05 was considered significant unless 
otherwise stated. 
 
RESULTS 
Literature search 
The literature search and study selection results are presented in Figure 2. There were 1689 
studies initially identified by the search strategy. After exclusion of duplicates 1277 titles and 
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abstracts were reviewed. Seventy-six full texts were retrieved and after irrelevant articles were 
excluded for; wrong exposure (29), wrong study design (22),wrong outcomes (5), not complete 
(1), not English (2); 17 articles remained. Two additional study was identified by hand 
searching reference lists. 
 
Study characteristics 
The characteristics of the included studies are presented in Table 1. Nineteen studies involving 
602,054 participants with more than 22,673 incidence of non-fatal or fatal CVD were included 
in the current meta-analysis (Cassidy et al., 2016; Cassidy et al., 2013; Cassidy et al., 2012; 
Goetz et al., 2016; Hirvonen et al., 2000; Hjartåker et al., 2015; Ivey et al., 2013; Jacques et 
al., 2015; Knekt et al., 1996; Lai et al., 2015; Larsson et al., 2013; McCullough et al., 2012; 
Mink et al., 2007; Mizrahi et al., 2009; Mursu et al., 2008; Ponzo et al., 2015; Sesso et al., 
2007; Tresserra-Rimbau et al., 2014; Zamora-Ros et al., 2013). All studies were published 
between 1996-2016, with seven studies conducted in USA (Cassidy et al., 2016; Cassidy et al., 
2013; Cassidy et al., 2012; Goetz et al., 2016; McCullough et al., 2012; Mink et al., 2007; Sesso 
et al., 2007) eleven in Europe (Hirvonen et al., 2000; Hjartåker et al., 2015; Jacques et al., 2015; 
Knekt et al., 1996; Lai et al., 2015; Larsson et al., 2013; Mizrahi et al., 2009; Mursu et al., 
2008; Ponzo et al., 2015; Tresserra-Rimbau et al., 2014; Zamora-Ros et al., 2013) and one in 
Australia (Ivey et al., 2013). Five studies reported anthocyanin intake (1.9-74.6 mg/day) 
(Cassidy et al., 2016; Cassidy et al., 2013; Cassidy et al., 2012; Jacques et al., 2015; Tresserra-
Rimbau et al., 2014), seven studies reported anthocyanidin intake (0-41 mg/day) (Goetz et al., 
2016; Ivey et al., 2013; Jacques et al., 2015; McCullough et al., 2012; Mink et al., 2007; Mursu 
et al., 2008; Ponzo et al., 2015; Zamora-Ros et al., 2013) and seven studies reported berry 
intake [0-365 g/day (Hirvonen et al., 2000; Knekt et al., 1996; Lai et al., 2015; Mizrahi et al., 
2009); 0-0.5 median servings/day (Hjartåker et al., 2015; Larsson et al., 2013; Sesso et al., 
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2007)]. The follow-up length of the included studies ranged from 4.3 to 41 years. All studies 
provided covariate-adjusted risk models (e.g. age, sex, BMI, smoking). Quality scores were ≥ 
6 stars (Table 1; supplemental), two studies were moderate quality (6 stars) (Hirvonen et al., 
2000; Ivey et al., 2013) and all other studies considered high quality (≥ 7 stars).  
 
Intake of anthocyanins and cardiovascular disease risk  
The random-effects pooled results for fully adjusted risk estimates of subgroups of CVD 
(Figure 3) showed an inverse association for intake of dietary anthocyanins and reduced risk 
of CHD (RR = 0.91, 95% CI: 0.83, 0.99; I2 = 12.0, Ph = 0.337) and CVD mortality (RR = 0.92, 
95% CI: 0.87, 0.97) with no between-study heterogeneity (I2 = 0.0, Ph = 0.584).  However, 
there was no relationship between the intake of these compounds and reduced risk of MI, stroke 
or total CVD. Subgroup analyses can be found in (Table 2; Supplemental). Reduced risk of 
CHD (RR = 0.84, 95% CI: 0.71, 0.98; I2 = 31.6, Ph = 0.227) and CVD mortality (RR = 0.92, 
95% CI: 0.87, 0.97; I2 = 0.0, Ph = 0.491) remained significant for anthocyanidin studies only, 
as opposed to studies which determined intake of berries or anthocyanins. Subgroup analysis 
also determined risk estimates to be significant for studies conducted in the USA for both CHD 
(RR = 0.84, 95% CI: 0.71, 0.98; I2 = 31.6, Ph = 0.227) and CVD mortality (RR = 0.89, 95% 
CI: 0.83, 0.96; I2 = 0.0 Ph = 0.691). Risk of MI, stroke and total CVD remained non-significant 
when stratified by exposure, sex, location, follow up and sample size. Stroke was further 
stratified by type (Figure 4), but no association was found between the intake of these 
compounds and reduced risk of cerebral infarction, ischaemic or hemmorrhagic strokes.   
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Publication bias and sensitivity analysis  
Egger’s test suggested the absence of significant publication for all studies based on each type 
of CVD (P ≥ 0.127). This was confirmed by visual inspection of the funnel plots (Figure 1; 
supplemental) which showed no substantial asymmetry. Overall, sensitivity analysis 
determined no materially different risk estimates indicating stable results between risk 
estimates of studies included in the pooled estimates (Figure 1; supplemental). 
 
DISCUSSION 
The current meta-analysis of nineteen prospective cohort studies is the largest, most 
comprehensive and contemporary to evaluate the association between dietary anthocyanin 
intake and risk of CVD. Our findings indicate that dietary intake of anthocyanins is inversely 
associated with CHD and CVD mortality (Figure 3), which is consistent with the findings of 
others (Grosso et al., 2017; Wang et al., 2014). Conversely, we found no relationship between 
the intake of these compounds and the risk of Stroke, MI or total CVD. This is surprising given 
that there is commonality in the aetiology of CVDs and a recent meta-analysis of randomised 
controlled trial showed and berry supplementation improved risk factors of CVD; specifically 
lipid profiles, systolic and diastolic blood pressure, which the authors speculate might be, at 
least partly, attributable to the anthocyanin content (Luís et al., 2018). Moreover, there is a 
growing body of evidence that increased flavonoid intake is associated with reduced risk of 
stroke (Tang et al., 2016) and total CVD (Wang et al., 2014). However, most of the prior 
epidemiologic evidence on flavonoids and CVD risk, specifically stroke, has focused on 
flavanones, flavones, flavonols, and flavan-3-ols (Tang et al., 2016) that might have different 
bioactivities compared to anthocyanins. Conversely, there are a number of weaknesses in the 
available data. Firstly, the majority of included studies in the current meta-analysis used FFQs 
to assess dietary intake of berries which have previously been reported to be less reliable to 
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assess berry intake compared to other foods (Bjelke, 1974). Secondly, most included studies 
used single assessments to categorise dietary anthocyanin intake, but this could likely change 
during the study (Jacques et al., 2015). Thirdly, although determination of 
anthocyanin/anthocyanidin intake is likely to be more comprehensive than intake of berries 
alone, there is the possibility of measurement error and misclassification. Furthermore, there is 
inherent difficulty in determining the intake of these compounds because the databases have 
missing foods and limited information on retention of these compounds following cooking 
(Zamora-Ros et al., 2011), and some studies would likely have used outdated databases. Thus, 
the different associations between CVDs might be confounded by suboptimal quantification of 
dietary intake of berries and/or anthocyanins, but could also be because of the limited number 
of studies found examining MI and total CVD. 
In the current meta-analysis, we found higher anthocyanin intake was associated with a 9% and 
8% reduced risk of CHD and CVD mortality, respectively. This is of great interest because 
CVD remains the most common cause of death worldwide, accounting for 45% of all deaths 
in Europe (Townsend et al., 2016) and is estimated to cost healthcare services £15.7 billion in 
the UK alone (Luengo-Fernandez et al., 2006). Our findings are of a similar magnitude to a 
recent meta-analysis that found that berry intake was associated with a significant reduction in 
all-cause mortality (RR = 0.92, 95% CI: 0.88, 0.97; I2 = 8.0, Ph =0.34) (Aune et al., 2017). 
Moreover, Guo and colleagues (2016) previously reported that risk of type II diabetes was 
reduced (5%) by increasing anthocyanin intake (7.5 mg/day; RR = 0.95; 95% CI: 0.93, 0.98) 
and berry intake (17 g/day; RR = 0.95; 95% CI: 0.91, 0.99), suggesting these compounds have 
a number of health benefits.  
Conversely, there was no relationship between intake of anthocyanins and risk of stroke. 
Further stratification by types of stroke because of possible differences in underlying 
mechanisms (Figure 4) revealed there was no relationship between the intake of these 
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compounds and cerebral infarction, ischaemic or hemorrhagic strokes. The reasons for the 
different risk estimates between anthocyanin intake and CHD versus stroke remains unknown, 
but might be because 1) anthocyanins do not circulate the brain in large enough doses to elicit 
neurovascular protection, or 2) the cerebrovasculature is more susceptible to atherosclerosis 
because of the smaller vessel diameters (Mursu et al., 2008). Our findings are consistent with 
a recent meta-analysis that reported highest berry intake was not associated with reduced risk 
of stroke (RR = 0.98, 95% CI: 0.86, 1.12) (Aune et al., 2017). The majority of included stroke 
studies in the current meta-analysis had berries as the exposure (Table 2; supplemental). Berries 
are a major source of anthocyanins, but these compounds are not uniformly distributed between 
these and other sources (Clifford, 2000; Horbowicz et al., 2008). In a subgroup-analysis we 
found more prominent relationships between anthocyanidins and reduced risk of CHD (16%) 
and CVD mortality (8%). Interestingly, because the included studies reported sources other 
than berries, such as red wine and cherries to significantly contribute to overall anthocyanin 
intake (Ponzo et al., 2015; Tresserra-Rimbau et al., 2014), perhaps the specific anthocyanins 
needs more careful consideration.  
A strength of this meta-analysis was the inclusion of multivariate-adjusted risk models that 
adjusted for important confounding variables. However, a limitation of the included studies is 
that intake of anthocyanins is positively correlated to fruit and vegetable intake and the 
beneficial nutrients associated with these, such as other flavonoids, vitamins, carotenoids and 
fibre (Zamora-Ros et al., 2013). Thus, because of multicollinearity, and because only some 
studies adjusted for some of these as covariates (Table 1), it is not possible to isolate whether 
the observed reduction in risk estimates is solely in response to intake of dietary anthocyanidins 
and not other bioactive compounds. We also found varying risk estimates for study locations; 
for example, reduced risk of CHD and CVD mortality only remained significant in the USA 
(Table 2; supplemental). It is plausible that this is attributable to differing dietary patterns and 
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inclusion of a diet richer in anthocyanidins (Wu et al., 2006; Zamora-Ros et al., 2011) and 
altered the bioavailabity of these compounds in vivo, especially in relation to interactions 
between diet and host microbiome (D’Archivio et al., 2010). It should also be acknowledged 
that other bioactive compounds, not just anthocyanidins, are likely to have synergistic 
interactions (Keane et al., 2016; Kirakosyan et al., 2010) and might not be as beneficial in 
isolation. Nonetheless, recent in vitro and human studies of anthocyanins and their relevant 
metabolites suggests that these compounds are responsible for some degree of cardioprotection 
(Fairlie-Jones et al., 2017; Reis et al., 2016). Although teleologically intuitive, this concept and 
the results of this meta-analysis should be interpreted cautiously given that previous studies 
have failed to demonstrate reduced risk of chronic diseases with antioxidant supplementation 
(Bjelakovic et al., 2012).  Therefore, future randomised controlled trials should determine the 
longitudinal effects of anthocyanin supplementation on CHD and CVD risk factors to support 
the findings of the current meta-analysis.  
In summary, this systematic review and meta-analysis provides further support that 
anthocyanins, specifically anthocyanidins, reduce the risk of CHD and CVD mortality, which 
from a public health perspective might help reduce the associated socioeconomic burdens. 
However, there was no relationship between the intake of these compounds and reduced risk 
of MI, stroke or total CVD; moreover, whether particular groups of anthocyanin-containing 
foods, such as berries, seem to be more beneficial than other fruits or vegetables remains to be 
established. Until more precise conclusions can be made, we recommend that dietary intake 
should include anthocyanidin-rich sources adjunct a varied diet of fruit and vegetables rich in 
other bioactive compounds. Further longitudinal randomised controlled trials determining the 
effect of anthocyanin intake on cardiovascular risk factors are needed to support the findings 
of the current meta-analysis.  
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Table 1. Characteristics of nineteen prospective cohort studies on dietary anthocyanin intake and risk of cardiovascular disease 
Reference Country Study cohort 
and no. of 
participants 
Sex Age 
range 
or 
mean 
(years) 
Follow-
up 
duration 
(years) 
Exposure and 
assessment 
method 
Outcome and 
no. of cases 
Covariate adjustments Study 
quality 
Cassidy et al. 
(2012) 
USA Nurses’ Health 
Study  
69622 
Females 30-55 14 Anthocyanins 
FFQ 
Ischemic 
stroke 
943 
Hemorrhagic 
stroke 
253 
Stroke 
1803 
Age, BMI, physical activity, alcohol 
consumption, energy intake, use of 
multivitamin supplements, use of 
aspirin, menopausal status, smoking 
and history of Type 2 diabetes, 
coronary heart disease, 
hypercholesterolemia, or 
hypertension.  
 
7 
Cassidy et al. 
(2013) 
USA Nurses’ Health 
Study II 
93600 
Females 25-42 18 Anthocyanins 
FFQ 
MI/CHD 
405 
Age, BMI, physical activity, alcohol 
consumption, energy intake, cereal 
fibre intake, fat intake, caffeine 
intake, use of aspirin, menopausal 
status, postmenopausal hormone 
use, oral contraceptive use, 
smoking, and family history of MI.  
 
7 
Cassidy et al. 
(2016) 
USA Health 
Professionals 
Follow-Up 
Study 
43880 
 
Males 32-81 24 Anthocyanins 
FFQ 
Total MI 
863 
Nonfatal MI 
482 
Fatal MI 
379 
Stroke 
346 
Ischemic 
stroke 
200 
BMI, physical activity, alcohol 
consumption, smoking, marital 
status, history of hypertension, 
history of hypercholesterolemia, 
quintiles of energy intake, cereal 
fibre, fat intake and folate, and 
family history of MI.  
 
7 
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Hemorrhagic 
stroke 
48 
Goetz et al. 
(2016) 
USA Reasons for 
Geographic 
and Racial 
Differences 
in Stroke 
16678 
Males/Females >45 6.06 Anthocyanidins 
FFQ 
MI/CHD 
589 
Age, energy intake, sex, physical 
activity, smoking demographic 
factors (race and region of 
residence), socioeconomic factors 
(household income and educational 
attainment), energy intake from 
sweetened foods and beverages, 
reported beer, liquor and fat intake. 
 
 
7 
Hirvonen et 
al., (2000) 
Finland Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention 
26593 
Males 50-69 5-8 Berries 
FFQ 
Cerebral 
infarction  
736 
Subarachnoid 
haemorrhage 
83 
Intracerebral 
haemorrhage 
95 
 
Age, BMI, height, supplementation 
group, systolic and diastolic blood 
pressures, serum total cholesterol, 
serum HDL cholesterol, smoking-
years, number of cigarettes daily, 
history of diabetes or coronary heart 
disease, alcohol intake, and 
education. 
 
6 
Hjartaker et 
al., (2015) 
Norway Norwegian 
Migrant cohort 
10718 
Males 33-73 41 Berries 
FFQ 
CVD mortality 
4595 
 
BMI, physical activity, beer, spirits, 
coffee, socioeconomic status 
(professional, administration, 
agricultural, industrial and other) 
and total smoking. 
 
7 
Ivey et al., 
(2013) 
Australia The Calcium 
Intake Fracture 
Outcome Age 
Related 
Extension 
Study 
Females >75 5 Anthocyanidin 
FFQ 
CVD mortality 
64 
Age, energy intake, BMI, previous 
atherosclerotic vascular disease, 
energy expended in physical 
activity, previous diabetes, anti-
hypertensive medication use, history 
of smoking and intakes of saturated 
6 
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1063 fat, fibre, protein, starch, vitamin C 
and alcohol at baseline. Sensitivity 
analysis was performed by repeating 
logistic regression analysis in 
participants without previous 
atherosclerotic vascular disease and 
diabetes at baseline. 
 
Jacques et al., 
(2015) 
USA Framingham 
Heart Study 
2880 
Males/Females 28-62 20 Anthocyanins 
FFQ 
Total CVD 
518 
CHD 
261 
 
Age, sex, current smoking status, 
BMI, total energy intake and 
fruit/vegetable intake. 
 
8 
Knekt et al., 
(1996) 
Finland The mobile 
clinic of the 
Finnish Social 
Insurance 
Institution 
2748 
 
Males 35-69 26 Berries 
Dietary history 
interview 
CHD 
324 
Age, BMI, smoking, serum 
cholesterol and hypertension. 
7 
Knekt et al., 
(1996) 
Finland The mobile 
clinic of the 
Finnish Social 
Insurance 
Institution 
2385 
 
Females 35-69 26 Berries 
Dietary history 
interview 
CHD 
149 
Age, BMI, smoking, serum 
cholesterol and hypertension. 
7 
Lai et al., 
(2015) 
UK UK Women’s 
Cohort Study 
30458 
Females 30-69 16.7 Berries 
FFQ 
CHD 
138 
Stroke 
148 
Total CVD 
286 
Age, BMI, physical activity, 
smoking status, socio-economic 
status, alcohol intake, total 
vegetable intake, and mutual 
adjustments for fruits that are not in 
the exposure category. 
 
 
7 
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Larsson et al.  
(2013) 
  
Sweden Swedish 
Mammography 
Cohort and the 
Cohort of 
Swedish Men  
74961 
Males/Females 45-83 10.2 Berries 
FFQ 
Cerebral 
infarction 
3159 
Intracerebral 
haemorrhage 
435 
Subarachnoid 
hemorrhage 
347 
Stroke 
4089 
Age, sex, BMI, smoking status and 
pack-years of smoking, education, 
total physical activity, aspirin use, 
history of hypertension, diabetes, 
family history of myocardial 
infarction, and intakes of total 
energy, alcohol, coffee, fresh red 
meat, processed meat, fish, total 
vegetable consumption and 
mutually adjusted for total fruit 
consumption. 
 
8 
McCullough et 
al., (2012) 
USA Cancer 
Prevention 
Study II 
Nutrition 
Cohort 
98469 
Males/Females 69.5 7 Anthocyanidins 
FFQ 
CVD mortality 
2771 
Age, smoking, beer and liquor 
intake, history of hypertension, 
history of cholesterol, family history 
of myocardial infarction, BMI, 
physical activity, energy intake, 
aspirin use, hormone replacement 
therapy (in women only), and sex (in 
combined model only). 
 
8 
Mink et al.,  
(2007) 
USA Iowa Women’s 
Health Study  
34489 
Females 55-69 16 Anthocyanidins 
FFQ 
CVD mortality 
2361  
CHD mortality 
1329 
Stroke 
469 
Age, energy intake, marital status, 
education, blood pressure, diabetes, 
BMI, waist-to-hip ratio, physical 
activity, smoking, and oestrogen 
use. 
 
7 
Mizrahi et al.,  
(2009) 
Finland Finnish Mobile 
Clinic 
Health 
Examination 
Survey 
3932 
Males/Females 40-74 24 Berries 
Dietary history 
interview 
Intracerebral 
haemorrhage 
58 
Ischaemic 
strokes 
335 
Age, sex, BMI, smoking, physical 
activity, serum cholesterol level, 
blood pressure and energy intake. 
8 
23 
 
 Stroke 
625 
 
Mursu et al., 
(2008) 
Finland Kuopio 
Ischaemic 
Heart Disease 
Risk Factor 
Study 
1950 
Males 42-60 15.2 Anthocyanidins 
4-day food diary 
Ischaemic 
stroke 
102 
CVD 
Mortality 
153 
Age, examination years, BMI, 
systolic blood pressure, 
hypertension medication, serum 
HDL- and LDL-cholesterol, serum 
TAG, maximal oxygen uptake, 
smoking, CVD in family, diabetes, 
alcohol intake, energy-adjusted 
intake of folate and vitamin E, total 
fat (percentage of energy) and 
saturated fat intake (percentage of 
energy). 
 
7 
Ponzo et al.,  
(2015) 
Italy Local Health 
Units of the 
province 
of Asti 
1658 
 
Males/Females 45-65 12 
 
 
Anthocyanidins 
FFQ 
CVD 
Mortality 
84 
Total CVD  
125 
 
Age, sex, BMI, education, living in 
a rural area, METs (hour/week), 
fibre, and saturated fatty acid 
intakes, alcohol intake, smoking, 
values of systolic and diastolic 
blood pressure, total and HDL 
cholesterol, fasting glucose, CRP, 
statin and aspirin use. 
 
7 
Sesso et al.,  
(2007) 
USA Women’s 
Health Study 
38176 
Females 54 10.1 Strawberries 
FFQ 
MI 
289 
Stroke 
339 
CVD mortality 
204 
Total CVD 
1004 
 
Age, randomized aspirin treatment, 
randomized vitamin E treatment, 
randomized beta-carotene 
treatment, and total energy intake, 
body mass index, exercise, alcohol 
intake, smoking, post-menopausal 
hormone use, and parental history of 
myocardial infarction 60 years, plus 
clinical factors: hypertension, 
hypercholesterolemia, and diabetes, 
plus dietary components related to 
7 
24 
 
strawberry intake: fruit and 
vegetables, fibre, folate, vitamin C, 
potassium, saturated fat, and total 
flavonoid intake. 
 
Tressera-
Rimbau et al.,  
(2014) 
Spain Prevención 
con Dieta 
Mediterránea  
7172 
Males/Females 66 4.3 Anthocyanins 
FFQ 
Total CVD 
273 
Age, sex, smoking, BMI, alcohol, 
energy, physical activity, family 
history of CVD, aspirin use, 
antihypertensive drugs, 
cardiovascular drugs, and diabetes 
status, plus intake of proteins, 
saturated fatty acids, 
polyunsaturated fatty acids, 
monounsaturated fatty acids, and 
cholesterol. 
 
7 
Zamora-Ros et 
al., (2013) 
Spain European 
Prospective 
Investigation 
into Cancer 
and Nutrition  
40622 
Males/Females 29-70 13.6 Anthocyanidins 
Computerized 
diet history 
questionnaire 
CVD mortality  
416 
Age, sex, BMI, education level, 
physical activity, tobacco smoking, 
alcohol lifetime, total energy, 
vitamin C and fibre intakes. 
7 
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoproteins; LDL, low-
density lipoproteins; food frequency questionnaire, FFQ; METs, metabolic equivalents; MI, myocardial infarction. 
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Figure 1. Major anthocyanidin compounds and their corresponding anthocyanin glycosides.  Glc = glucose.
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Figure 2. PRISMA flow chart for literature search and study selection. 
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Figure 3. Random-effects analysis of fully-adjusted risk estimates of cardiovascular diseases 
(CVD) by highest versus lowest dietary anthocyanin intake. Grey shaded area represents 
proportional weighting and the diamond represent summary relative risk for coronary heart 
disease (CHD); stroke; total CVD; myocardial infarction (MI) and CVD mortality, 
respectively. 
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Figure 4. Random-effects analysis of fully-adjusted risk estimates of stroke by highest versus 
lowest dietary anthocyanin intake. Grey shaded area represents proportional weighting and the 
diamond represent summary relative risk for stroke subgroups.
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Supplemental Table 1. Newcastle-Ottawa scale quality assessment of included studies 
Study Representati
veness of 
exposed 
cohort 
Selection of  
unexposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was 
present at start 
of study 
Control for 
important 
factors or 
additional 
factors 
Outcome 
assessment 
Follow-up 
long enough 
for outcomes 
to occur† 
Adequacy of 
follow-up 
of cohorts† 
 
Total 
quality 
scores 
Cassidy et al. (2012) ̶ 
  
̶ 
      
7 
Cassidy et al. (2013) ̶ 
  
̶ 
      
7 
Cassidy et al. (2016) ̶ 
  
̶ 
      
7 
Goetz et al. (2016)   ̶     
̶ 
  
7 
Hirvonen et al., (2000) ̶ 
  
̶ 
    
̶ 
  
6 
Hjartaker et al., (2015)  ̶  ̶       
7 
Ivey et al., (2013) ̶  ̶    ̶  6 
Jacques et al., (2015)    ̶       
8 
Knekt et al., (1996)    ̶       
7 
Knekt et al., (1996)    ̶       
7 
Lai et al., (2015)  ̶ 
  
̶ 
      
7 
Larsson et al. (2013) 
   
̶ 
      
8 
McCullough et al., (2012)   ̶     
̶ 
  
7 
 
Mink et al., (2007) ̶ 
  
̶ 
      
7 
Mizrahi et al., (2009)   ̶       
8 
30 
 
Mursu et al., (2008)  ̶ 
  
̶ 
      
7 
Ponzo et al., (2015) ̶ 
  
̶ 
      
7 
Sesso et al., (2007) ̶ 
  
̶ 
      
7 
Tressera-Rimbau et al., (2014)   ̶     
̶ 
  
7 
Zamora-Ros et al., (2013)   ̶       
7 
†(follow-up of ≥ 10 years and >80% assigned one star each)  
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Supplemental Table 2. Subgroup analysis of different cardiovascular diseases  
Subgroup 
Summary RR 
(95% CI) 
Heterogeneity No. of 
cohorts 
References 
Ph value  I
2 
(%) 
 
Coronary Heart Disease  
Exposure       
Berries  0.95 (0.75, 1.21) 0.473  0.0 2 [1, 2] 
Anthocyanidins 0.84 (0.71, 0.98) 0.227  31.6 2 [3, 4] 
Anthocyanins 0.98 (0.86, 1.12) ̶  ̶ 1 [5] 
Sex       
Males 1.21 (0.89, 1.64) ̶  ̶ 1 [1] 
Females 0.81 (0.65,1.01) 0.264  24.8 3 [1-3] 
Males/Females 0.87 (0.65, 1.15) 0.061  71.5 2 [4, 5] 
Location       
Europe 0.97 (0.87, 1.09) 0.751  0.0 3 [1, 2, 5] 
USA 0.84 (0.71, 0.98) 0.227  31.6 2 [3, 4] 
Follow up        
≥ 10 years 0.93 (0.85, 1.01) 0.580  0.0 4 [1-3, 5] 
< 10 years 0.73 (0.55, 0.96) ̶  ̶ 1 [4] 
Sample size       
≥ 10000 0.85 (0.76,0.95) 0.449  0.0 3 [2-4] 
< 10000 0.98 (0.87, 1.10) 1.000  0.0 2 [1, 5] 
CVD mortality  
Exposure       
Berries  0.76 (0.38, 1.55) ̶  ̶ 1 [6] 
Anthocyanidins 0.92 (0.87, 0.97) 0.491  0.0 6 [3, 7-11] 
Sex       
Males 0.92 (0.79, 1.07) 0.772  0.0 2 [7, 8] 
Females 0.89 (0.82, 0.96) 0.603  0.0 4 [3, 6, 8, 9] 
Males/Females 0.91 (0.81, 1.01) 0.176  42.4 3 [8, 10, 11] 
Location       
Australia 0.67 (0.33, 1.34) ̶  ̶ 1 [9] 
Europe 0.95 (0.88, 1.03) 0.464  0.0 3 [7, 10, 11] 
USA 0.89 (0.83, 0.96) 0.691  0.0 3 [3, 6, 8] 
Follow up        
32 
 
≥ 10 years 0.92 (0.87, 0.97) 0.562  0.0 6 [3, 6-8, 10, 
11] 
< 10 years 0.67 (0.33, 1.34) ̶  ̶ 1 [9] 
Sample size       
≥ 10000 0.92 (0.87, 0.97) 0.451  0.0 4 [3, 6, 8, 10] 
< 10000 0.78 (0.55, 1.10) 0.552  0.0 3 [7, 9, 11] 
       
Myocardial infarction 
Exposure       
Berries  1.84 (1.04, 3.24) ̶  ̶ 1 [6] 
Anthocyanins 0.84 (0.60, 1.18) 0.048  74.5 2 [12, 13] 
Sex       
Males 0.97 (0.87, 1.07) ̶  ̶ 1 [13] 
Females 1.09 (0.41, 2.88) 0.003  88.5 2 [6, 12] 
Location       
USA 1.00 (0.68, 1.46) 0.010  78.1 3 [6, 12, 13] 
Follow up        
≥ 10 years 1.00 (0.68, 1.46) 0.010  78.1 3 [6, 12, 13] 
Sample size       
≥ 10000 1.00 (0.68, 1.46) 0.010  78.1 3 [6, 12, 13] 
Stroke  
Exposure       
Berries  1.00 (0.88, 1.14) 0.076  49.9 6 [2, 6, 14-17] 
Anthocyanidins 1.00 (0.82, 1.21) 0.678  0.0 2 [3, 7] 
Anthocyanins 0.98 (0.88, 1.09) 0.720  0.0 2 [13, 18] 
Sex       
Males 0.94 (0.85, 1.04) 0.564  0.0 4 [7, 13, 14, 17] 
Females 1.06 (0.89, 1.27) 0.478  0.0 3 [2, 3, 6] 
Males/Females 1.04 (0.86, 1.27) 0.114  60.0 2 [15, 16] 
Location       
Europe 0.98 (0.87, 1.10) 0.132  41.1 6 [2, 7, 14-17] 
USA 1.00 (0.91, 1.10) 0.551  0.0 4 [3, 6, 13, 18] 
Follow up        
≥ 10 years 1.03 (0.96, 1.09) 0.567  0.0 9 [2, 3, 6, 7, 13, 
15-18] 
< 10 years 0.84 (0.70, 1.01) ̶  ̶ 1 [14] 
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Sample size       
≥ 10000 1.00 (0.93, 1.09) 0.201  28.5 8 [2, 3, 6, 13, 
14, 16-18] 
< 10000 0.92 (0.74, 1.13) 0.895  0.0 2 [7, 15] 
Total CVD  
Exposure       
Berries  1.12 (0.80, 1.56) 0.220  33.5 2 [2, 6] 
Anthocyanidins 0.56 (0.36, 0.88) ̶  ̶ 1 [11] 
Anthocyanins 0.88 (0.67, 1.17) 0.206  37.5 2 [5, 19] 
Sex       
Females 1.12 (0.80, 1.56) 0.220  33.5 2 [2, 6] 
Males/Females 0.75 (0.52, 1.09) 0.041  68.7 3 [5, 11, 19] 
Location       
Europe 0.80 (0.61, 1.04) 0.094  53.1 4 [2, 5, 11, 19] 
USA 1.27 (0.94, 1.72) ̶  ̶ 1 [6] 
Follow up        
≥ 10 years 0.92 (0.71, 1.19) 0.031  66.1 4 [2, 5, 6, 11] 
< 10 years 0.67 (0.39, 1.13) ̶  ̶ 1 [19] 
Sample size       
≥ 10000 1.12 (0.80, 1.56) 0.220  33.5 2 [2, 6] 
< 10000 0.75 (0.52, 1.09) 0.041  68.7 3 [5, 11, 19] 
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Supplemental Figure 1a. Funnel 
plot and sensitivity analysis for 
anthocyanin intake and risk of 
CHD. 
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Supplemental Figure 1b. Funnel 
plot and sensitivity analysis for 
anthocyanin intake and risk of 
CVD mortality. 
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Supplemental Figure 1c. Funnel 
plot and sensitivity analysis for 
anthocyanin intake and risk of MI. 
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Supplemental Figure 1d. Funnel 
plot and sensitivity analysis for 
anthocyanin intake and risk of 
Stroke. 
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Supplemental Figure 1e. Funnel 
plot and sensitivity analysis for 
anthocyanin intake and risk of 
total CVD. 
